Comparing Clarithromycin and Azithromycin for MAC Lung Infections
Official title: CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
Run by Centre Hospitalier Universitaire, Amiens · NCT03236987 · Data updated 2026-11-12
This study is testing whether clarithromycin or azithromycin works better and is safer for people with lung infections caused by Mycobacterium avium complex.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 424 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 3 sites (Amiens, Picardie and 2 other locations) |
| Status | Recruiting |
| Started | February 5, 2018 |
| Main results expected | February 5, 2028 |
| Study ends | February 5, 2029 |
| Registry record updated | November 19, 2025 |
| Trial ID | NCT03236987 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of MAC lung infection requiring treatment.
✕Probably not a fit
Patients with known hypersensitivity to the study medications, those with resistant strains of MAC, or individuals with certain health conditions such as severe renal insufficiency may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to compare the efficacy and safety of clarithromycin and azithromycin in treating lung infections caused by Mycobacterium avium complex (MAC). It focuses on patients who meet specific clinical, radiological, and microbiological criteria for MAC infection. The study will involve administering either clarithromycin or azithromycin alongside rifampicin and ethambutol to evaluate which treatment is more effective and better tolerated. The trial is significant as it addresses a gap in existing research regarding the treatment of pulmonary MAC infections.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients suffering from MAC lung infections, potentially reducing side effects and enhancing efficacy.
How similar studies have gone: While previous studies have compared macrolides for MAC infections, this trial is novel as it specifically focuses on pulmonary infections and has not been previously conducted.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients 18 years of age or older * having a positive Mycobacterium avium complex sample showing the ATS / IDSA infection criteria and requiring treatment * ATS / IDSA infection criteria combine clinico-radiological criteria, associated with microbiological criteria * the exclusion of any other diagnosis on the thoracic CT, fibroscopy and bacteriological samples Exclusion Criteria: * Known hypersensitivity to one of the study molecules (rifampicin, ethambutol, azithromycin, clarithromycin) * Relapse of an MAC infection, * Strain resistant to macrolides, based on genotyping susceptibility testing (genotyping susceptibility testing must be done before inclusion) * Treatment that interacts with cytochrome p450 that can not be replaced by another therapeutic, * HIV serology 1 and 2, * Renal insufficiency with creatinine clearance less than 30 ml / min, * Pregnancy and breast feeding, * Contra-indication to one of the antibiotics, * Impossibility to follow the protocol due in particular to drug addiction according to the investigator, * Limited life expectancy, less than 6 months, * Patient already participating in a clinical trial on a medical treatment or a therapeutic strategy for non-tuberculous mycobacteria.
Where it's running
-
CHU Angers
Angers, France Recruiting -
Saint Joseph Hospital
Marseille, France Recruiting -
CHU Amiens Picardie
Amiens, Picardie, France Not yet recruiting
Study contacts
- Study coordinator: Claire ANDREJAK, PhD
- Email: andrejak.claire@chu-amiens.fr
- Phone: +33322087893
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
This study is testing a new imaging method using a special probe to see if it can help doctors better identify lung lesions in patients.
-
Using breath analysis to identify multiple lung diseases
This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.
-
Evaluating the effects of lying face down after major abdominal surgery
This study is testing whether lying face down after major abdominal surgery helps patients recover better and have fewer lung problems.
-
Registry for pleural fluid samples from lung cancer and infection patients
This study is collecting fluid samples from patients with lung cancer or lung infections to see if they can help create better tests and treatments for these conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.